‪László Tiszlavicz‬ - ‪Google Scholar‬

Prostate intraductal carcinoma pathology outlines. Central Library - Semmelweis Publications


    The current situation of cancer morbidity and mortality in the light of the National Cancer Registry, Hungary.

    prostate intraductal carcinoma pathology outlines

    Prostate ; — Molecular pathology of prostate cancer. Molecular subtypes and perspectives of targeted therapies in prostate cancer.

    • By the end of the academic year, a basic clinicopathological affinity and competence in differential diagnosis is required of the students.
    • В таком случае он должен обращаться описывает.

    Molecular underpinnings of systemic treatment resistance in metastatic castration-resistant prostate cancer. Integrative clinical genomics of advanced prostate cancer.

    Cell ; — Prostate intraductal carcinoma pathology outlines and somatic mutations in prostate cancer for the clinician.

    J Natl Compr Canc Netw. Germline genetic testing in prostate cancer — further enrichment in variant histologies?

    prostate intraductal carcinoma pathology outlines

    Oncoscience ; 5: 62— Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. Eur Urol. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol.

    prostate intraductal carcinoma pathology outlines

    J Clin Oncol ; — Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.

    Patients newly randomized or already randomized in the pixantrone group can be included. Pathology and immunohistochemistry reports documenting the current histological diagnosis according to World Health Organization WHO classification must be reviewed by the sponsor or designee prior to randomization. Received a rituximab-containing multi-agent regimen eg, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone [R-CHOP]; rituximab, cyclophosphamide, vincristine, prednisone [R-CVP]; or bendamustine-R 7. Not eligible for high-dose myeloablative chemotherapy and SCT.

    Cancer ; — Medical treatment options in BRCA-associated cancers. Genomic analysis of three metastatic prostate prostatita tratament forum patients with exceptional responses to carboplatin indicating different types of DNA repair deficiency.

    prostate intraductal carcinoma pathology outlines

    Prostate Cancer. Version 2.

    prostate intraductal carcinoma pathology outlines

    Mutations in BRCA2 and taxane resistance in prostate cancer. Sci Rep.

    prostate intraductal carcinoma pathology outlines